Pharmaceutical composition
AssigneeAktiebolaget Astra
InventorsBertil F. H. Eriksson, Raymond F. Schinazi
Life of this patent
Estimating the term…
Abstract
Combinations of 3'-azido-3'deoxythymidine and phsphonoformate have been found to produce a synergistic inhibitory effect against human immunodeficiency virus (HIV).
Claims3
A pharmaceutical composition comprising a combination of a first component which is 3'-azido-3'-deoxythymidine (AZT) or its 5'-triphosphate (AZT-TP), and a second component which is phosphonoformic acid or a therapeutically acceptable salt thereof (PFA), and wherein the ratio on a molar basis of AZT or AZT-TP to PFA is in the range from 1:200 to 1:8000, to enhance drug efficacy.
A method for the treatment of patients with drug-resistant variants of HIV that includes administering an effective amount of 3'-azido-3'-deoxythymidine (AZT) or its triphosphate and an effective amount of phosphonoformic acid or a therapeutically acceptable salt thereof (PFA), to enhance drug efficacy.
Dependencies are inferred from the claim text.